3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Brain Neoplasms
6
Glioblastoma
4
Central Nervous System Neoplasms
3
Neuroblastoma
2
Neoplasms, Germ Cell and Embryonal
2
Lung Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Astrocytoma
2
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Tongue Neoplasms
1
Thyroid Neoplasms
1
Thymus Neoplasms
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Kaposi
1
Sarcoma
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pinealoma
1
Pheochromocytoma
1
Interventions
Magnetic Resonance Spectroscopy
7
gallium Ga 68 dotatate
6
lutetium Lu 177 dotatate
4
Fluorodeoxyglucose F18
3
3-Iodobenzylguanidine
3
177Lu-octreotide, DOTA(0)-Tyr(3)-
3
fluorodopa F 18
2
Specimen Handling
2
FAPI-46
2
Everolimus
2
Erlotinib Hydrochloride
2
vandetanib
1
romidepsin
1
pertuzumab
1
pentetreotide
1
olaparib
1
fludarabine phosphate
1
entrectinib
1
dactolisib
1
cabozantinib
1
atezolizumab
1
arginyllysine
1
amino-acid, glucose, and electrolyte solution
1
alectinib
1
Whole Body Imaging
1
Tretinoin
1
Respiratory Therapy
1
Quality of Life
1
Positron-Emission Tomography
1
Patient Reported Outcome Measures
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
Immunotherapy
×
CNS
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled